One year of treatment with saroglitazar, Zydus Therapeutics’ experimental oral candidate, outperformed a placebo at normalizing markers of liver injury in people with primary biliary cholangitis (PBC), according to top-line data from a Phase 2b/3 clinical trial. The new findings mean that the Phase 2b/3 EPICS-III study (NCT05133336) — which included adults who did not […] The post New trial data show saroglitazar works to ease liver damage in PBC appeared first on Liver Disease News.| Liver Disease News – The Web's Daily Resource for Liver Disease News
A Houston-based company is taking a medicine-free approach to target brain neurologically associated with mental illness. Nexalin Technology’s patented, FDA-cleared frequency-based waveform targets key centers of the midbrain to support the normalization of neurochemicals through a process known as Transcranial Alternating Current Stimulation (tACS). Delivered via a non-invasive device, the treatment gently stimulates the hypothalamus and midbrain, helping to “reset networks associated wi...| InnovationMap
Discover five South Korean biotechs that have received funding in recent years and are broadening R&D in various therapeutics areas. The post Five biotech companies in South Korea you should know about appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is giv...| Labiotech.eu
The post The August 2025 <em>News from ECOG-ACRIN</em> blog is now available appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
A six-week psychotherapy program, tailored specifically for people with neuromyelitis optica spectrum disorder (NMOSD) and delivered via telehealth, helped to ease anxiety and depression in adults with these conditions — with benefits lasting up to three months after treatment. These are the findings of a U.S. pilot clinical trial (NCT05840055) that tested ACT with NMOSD, an […] The post Telehealth offers a new path for improving mental health in NMOSD appeared first on Neuromyelitis News.| Neuromyelitis News – The Web's Daily Resource for Neuromyelitis Optica News
The first three Parkinson's patients who received ANPD001 saw improvements in motor symptoms and daily functioning, early trial data showed.| Parkinson's News Today
After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in PH-ILD patients.| Pulmonary Hypertension News
Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly skin cancer.| Labiotech.eu
The post A new biomarker, KIM-1, may predict outcomes and response in kidney cancer (mentions E2805/ASSURE) appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped capital.| Labiotech.eu
The post Treatment headway gives much-needed hope in small-cell lung cancer (discusses EA5161 and other trials) appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
The post Trial Spotlight: Dr. Ken Cardona gives an update on the STRASS 2 sarcoma trial (EA7211) appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
A study from the Barcelona Institute for Global Health revealed that ivermectin, usually used to treat river blindness and scabies, can reduce malaria transmission. The BOHEMIA trial is the largest study on ivermectin for malaria, and results revealed that the pill reduced malaria by 26%. As mosquitoes become more resistant to insect repellent and other… The post This pill makes blood deadly to mosquitoes and reduced malaria by 26% appeared first on Drug Discovery and Development.| Drug Discovery and Development
The first participants in a Phase 2 clinical trial testing brepocitinib, Roivant’s experimental oral treatment, in adults with cutaneous sarcoidosis have been dosed, and top-line results are expected in the second half […] The post Brepocitinib Phase 2 trial doses first cutaneous sarcoidosis patients appeared first on Sarcoidosis News.| Sarcoidosis News – The Web's Daily Resource for Sarcoidosis News
New narcolepsy treatments are being tested in the clinic, and recently, some of them have made promising strides. How far along are they?| Labiotech.eu
Treatment with esketamine, a compound related to ketamine, led to some behavioral improvements in three girls with Rett syndrome in a trial.| Rett Syndrome News
When Kathryn Gallagher’s 13-year-old artificial heart valve started to fail, the oxygen-rich blood feeding her organs, tissues, and muscles slowed to a trickle. The condition, known as aortic valve stenosis, brought everything she loved doing to a standstill. The 80-year-old weightlifter and exercise junky could barely climb the stairs in her house without having to…| Kaiser Permanente Look insideKP Northern California
Zilbrysq was found safe and effective in a clinical trial for generalized myasthenia gravis patients who switched from other C5 inhibitors.| Myasthenia Gravis News
BioXcel plans to test BXCL501 for treating agitation in Alzheimer’s disease dementia in patients in nursing and assisted living facilities.| Alzheimer's News Today
GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.| Pulmonary Fibrosis News
Target enrollment is complete for a Phase 1b trial testing the safety and tolerability of GT-02287 in people with Parkinson’s disease.| Parkinson's News Today
Efgartigimod is entering a Phase 3 clinical trial after data from a proof-of-concept Phase 2 trial showed it outperformed a placebo at easing symptoms and signs of primary Sjögren’s disease, the treatment’s developer said. Argenx shared the data at the European Congress of Rheumatology (EULAR) 2025, held June 11-14 in Barcelona, in a presentation, “Treatment of […] The post Efgartigimod in Phase 3 testing for Sjogren’s as data show promise appeared first on Sjogren's Syndrome News.| Sjogren's Syndrome News – The Web's Daily Resource for Sjogren's Syndrome News
Taysha Gene Therapies announced details for the second part of a clinical trial testing Rett gene therapy TSHA-102.| Rett Syndrome News
GRI Bio reached an interim enrollment goal for a clinical trial testing GRI-0621, a therapy targeting natural killer T-cells to treat IPF.| Pulmonary Fibrosis News
Pending regulatory clearance in Colombia, Unravel Biosciences will launch a trial this summer testing Rett treatment RVL001 in 15 patients.| Rett Syndrome News
by Gertrud U. Rey The number of measles cases is steadily increasing across the United States, especially in areas with low vaccination rates. Instead of recommending that children be vaccinated with the measles, mumps, and rubella (MMR) vaccine, US Health and Human Services Secretary Robert F. Kennedy Jr. continues to promote ideas that are rooted …Vitamin A, Cod Liver Oil, and Measles Read More »| Virology Blog
Study Shows Plant Protein Shake Better for Blood Sugar Control than Dairy-Based Whey Full publication – Nutrients 2021 A study published June 23, 2021 in Nutrients aimed to look at the short-term effects on glycemic indices, gut hormones and subjective appetite ratings of two plant proteins (potato or rice) compared to an animal/dairy-based whey protein. [...] The post Study Shows Plant Protein Shake Better for Blood Sugar Control than Dairy-Based Whey appeared first on Axiom Foods.| Axiom Foods
A Phase 2 clinical trial to test MRM-3379, an experimental oral treatment for fragile X syndrome, is expected to launch in 2025. Mirum Pharmaceuticals announced the plan in a company press release reporting financial results and business updates. It didn’t provide details on the trial’s design or location. In October, Mirum acquired global rights to […] The post Mirum plans 2025 Phase 2 trial testing fragile X treatment appeared first on Fragile X News Today.| Fragile X News Today – The Web's Daily Resource for Fragile X News
The first four Rett syndrome patients treated with the gene therapy candidate NGN-401 have seen meaningful gains in skills, data show.| Rett Syndrome News
The Canadian government has cleared KGK Science's Phase 2a trial testing NM-1001, a psilocybin microdose therapy, in fragile X syndrome.| Fragile X News Today
Acupuncture is a form of alternative medicine that has been around for centuries, but a new study shows it could have a new use: preventing UTIs.| Scienceline
In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused pipelines.| Labiotech.eu
The first patient has been dosed in a Phase 2a trial of Parkinson's therapy VTX3232, an oral medication designed to reduce inflammation.| Parkinson's News Today
The FDA has approved a Phase 2 trial to test SPG601, an oral treatment candidate, in men with fragile X syndrome.| Fragile X News Today
Treatment with telitacicept for almost six months lessened disease activity in gMG adults positive for anti-AChR antibodies, per a study.| Myasthenia Gravis News
Iaso Bio has received clearance from the FDA to start clinical trials to test its CAR T-cell therapy equecabtagene autoleucel in MS patients.| Multiple Sclerosis News Today
Uncover the promise of KRAS inhibitors in cancer treatment, as evidenced by a $200 million investment in BridgeBio's spinout.| Labiotech.eu
The first patient was dosed in the U.S. as part of a clinical trial testing of NK cell therapy candidate AlloNK for lupus nephritis.| Lupus News Today
Seattle Children's will start a clinical trial testing CAR T-cell therapy in children with lupus this summer after getting FDA clearance.| Lupus News Today
Let us take a look at how the hunt for amyotrophic lateral sclerosis (ALS) drugs has advanced over the past few years.| Labiotech.eu
Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases.| Labiotech.eu